Previous 10 | Next 10 |
Arena Pharmaceuticals (NASDAQ: ARNA ): Q3 GAAP EPS of -$1.46 misses by $0.14 . Revenue of $1.35M (-62.2% Y/Y) misses by $0.71M . Press Release More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
SAN DIEGO , Nov. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2019 . "Arena continues to have a strong 2019 and we remain highly focused on achi...
Arena Pharmaceuticals (NASDAQ: ARNA ) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close. The consensus EPS Estimate is -$1.31 (-87.1% Y/Y) and the consensus Revenue Estimate is $2.06M (-42.8% Y/Y). Over the last 2 years, arna has beaten EPS est...
AAXN , AGO , AIRG , AL , ALTR , AMBC , AMH , AMPH , AQN , ARLO , ARNA , ATVI , AVID , BE , BEDU , BGNE , BKNG , BOLD , CABO , CDAY , CHUY , COLD , CORT , CTRE , CUTR , CWH , CYRX , DBX , DIS , EB , ENLC , ENV , FARM , FSLY , G , GDOT , GH , GPRO , GSBD...
SAN DIEGO , Nov. 6, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance, metabolic disposition, and pharmacokinetics (PK) of etrasimod in healthy adult male volunteers. Etrasimod is an investigational next-genera...
SAN DIEGO , Oct. 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019 , after the close of the U.S. financial markets. The Company will host a conferen...
- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO , Oct. 28, 2019 /PRNewswire/ -- Arena Pharm...
SAN DIEGO, Calif. , Oct. 22, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) ...
Translate Bio ( TBIO ) has a major catalyst that is approaching towards the end of October of 2019. This will be both an oral and poster presentation of phase 1/2 study data from about 12 patients with cystic fibrosis ((CF)). These results will be presented on November 1, 2019, at the 33rd...
SAN DIEGO , Oct. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) ...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...